These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
330 related articles for article (PubMed ID: 37961996)
41. Crosstalk between m6A and coding/non-coding RNA in cancer and detection methods of m6A modification residues. Meng Q; Schatten H; Zhou Q; Chen J Aging (Albany NY); 2023 Jul; 15(13):6577-6619. PubMed ID: 37437245 [TBL] [Abstract][Full Text] [Related]
42. Effect of circular RNAs and N6-methyladenosine (m6A) modification on cancer biology. Zhang G; Hou J; Mei C; Wang X; Wang Y; Wang K Biomed Pharmacother; 2023 Mar; 159():114260. PubMed ID: 36657303 [TBL] [Abstract][Full Text] [Related]
43. Targeting IGF2BP3 in Cancer. Liu X; Chen J; Chen W; Xu Y; Shen Y; Xu X Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298373 [TBL] [Abstract][Full Text] [Related]
44. The role of N Wang K; Wang L; Chen X; Gu J; Cheng X Epigenomics; 2023 Nov; 15(22):1221-1232. PubMed ID: 38009226 [TBL] [Abstract][Full Text] [Related]
45. The role of m6A RNA methylation in cancer. Sun T; Wu R; Ming L Biomed Pharmacother; 2019 Apr; 112():108613. PubMed ID: 30784918 [TBL] [Abstract][Full Text] [Related]
46. Novel insights into the interaction between N6-methyladenosine methylation and noncoding RNAs in musculoskeletal disorders. Han J; Kong H; Wang X; Zhang XA Cell Prolif; 2022 Oct; 55(10):e13294. PubMed ID: 35735243 [TBL] [Abstract][Full Text] [Related]
47. Progress of long noncoding RNAs in anti-tumor resistance. Zhang H; Wang Y; Liu X; Li Y Pathol Res Pract; 2020 Nov; 216(11):153215. PubMed ID: 32979688 [TBL] [Abstract][Full Text] [Related]
48. Construction of an N6-methyladenosine lncRNA- and immune cell infiltration-related prognostic model in colorectal cancer. Yu ZL; Zhu ZM Protoplasma; 2022 Jul; 259(4):1029-1045. PubMed ID: 34734333 [TBL] [Abstract][Full Text] [Related]
49. Comprehensive Analysis of N6-Methyladenosine-Related lncRNA Signature for Predicting Prognosis and Immune Cell Infiltration in Patients with Colorectal Cancer. Zhao Z; Yang YB; Li XY; Li XG; Chu XD; Lin ZB; Zhang YR; Guo YG; Ding H; Pan YL; Wang L; Pan JH Dis Markers; 2021; 2021():8686307. PubMed ID: 34745388 [TBL] [Abstract][Full Text] [Related]
50. Long non-coding RNAs (lncRNAs) signaling in cancer chemoresistance: From prediction to druggability. Eptaminitaki GC; Stellas D; Bonavida B; Baritaki S Drug Resist Updat; 2022 Dec; 65():100866. PubMed ID: 36198236 [TBL] [Abstract][Full Text] [Related]
51. Breast Cancer Chemoresistance: Insights into the Regulatory Role of lncRNA. Ahmadpour ST; Orre C; Bertevello PS; Mirebeau-Prunier D; Dumas JF; Desquiret-Dumas V Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958880 [TBL] [Abstract][Full Text] [Related]
52. N6-Methyladenosine-Related lncRNA Signature Predicts the Overall Survival of Colorectal Cancer Patients. Song W; Ren J; Yuan W; Xiang R; Ge Y; Fu T Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573357 [TBL] [Abstract][Full Text] [Related]
53. The m6A methyltransferase RBM15 affects tumor cell stemness and progression of cervical cancer by regulating the stability of lncRNA HEIH. Quan Y; Zhou M; Li J; Yang Y; Guo J; Tang T; Liu P Exp Cell Res; 2024 Mar; 436(2):113924. PubMed ID: 38280435 [TBL] [Abstract][Full Text] [Related]
54. m6A methyltransferase Wilms' tumor 1-associated protein facilitates cell proliferation and cisplatin resistance in NK/T cell lymphoma by regulating dual-specificity phosphatases 6 expression via m6A RNA methylation. Ma H; Shen L; Yang H; Gong H; Du X; Li J IUBMB Life; 2021 Jan; 73(1):108-117. PubMed ID: 33205540 [TBL] [Abstract][Full Text] [Related]
55. Molecular mechanism analysis of m6A modification-related lncRNA-miRNA-mRNA network in regulating autophagy in acute pancreatitis. Li X; Qin H; Anwar A; Zhang X; Yu F; Tan Z; Tang Z Islets; 2022 Dec; 14(1):184-199. PubMed ID: 36218109 [TBL] [Abstract][Full Text] [Related]
56. N6-methyladenosine functions and its role in skin cancer. Ran Y; Yan Z; Jiang B; Liang P Exp Dermatol; 2023 Jan; 32(1):4-12. PubMed ID: 36314059 [TBL] [Abstract][Full Text] [Related]
57. Epitranscriptomic orchestrations: Unveiling the regulatory paradigm of m6A, A-to-I editing, and m5C in breast cancer via long noncoding RNAs and microRNAs. Yin Q; Qu Z; Mathew R; Zeng L; Du Z; Xue Y; Liu D; Zheng X Cell Biochem Funct; 2024 Apr; 42(3):e3996. PubMed ID: 38561942 [TBL] [Abstract][Full Text] [Related]
58. Research Progress on Long Noncoding RNAs and N6-Methyladenosine in Hepatocellular Carcinoma. Zhang W; Wu W; Meng Q; Yang L; Yuan J; Tian Z; Ding R; Zhang X; Wang J; Tao K Front Oncol; 2022; 12():907399. PubMed ID: 35936671 [TBL] [Abstract][Full Text] [Related]
59. Crosstalk between m6A modification and non-coding RNAs in HCC. Qiu Z; Yuan X; Wang X; Liu S Cell Signal; 2024 May; 117():111076. PubMed ID: 38309550 [TBL] [Abstract][Full Text] [Related]
60. Functions of N6-methyladenosine and its role in cancer. He L; Li H; Wu A; Peng Y; Shu G; Yin G Mol Cancer; 2019 Dec; 18(1):176. PubMed ID: 31801551 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]